323 related articles for article (PubMed ID: 10945872)
1. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.
Reavill C; Taylor SG; Wood MD; Ashmeade T; Austin NE; Avenell KY; Boyfield I; Branch CL; Cilia J; Coldwell MC; Hadley MS; Hunter AJ; Jeffrey P; Jewitt F; Johnson CN; Jones DN; Medhurst AD; Middlemiss DN; Nash DJ; Riley GJ; Routledge C; Stemp G; Thewlis KM; Trail B; Vong AK; Hagan JJ
J Pharmacol Exp Ther; 2000 Sep; 294(3):1154-65. PubMed ID: 10945872
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat.
Stemp G; Ashmeade T; Branch CL; Hadley MS; Hunter AJ; Johnson CN; Nash DJ; Thewlis KM; Vong AK; Austin NE; Jeffrey P; Avenell KY; Boyfield I; Hagan JJ; Middlemiss DN; Reavill C; Riley GJ; Routledge C; Wood M
J Med Chem; 2000 May; 43(9):1878-85. PubMed ID: 10794704
[TBL] [Abstract][Full Text] [Related]
3. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
Sautel F; Griffon N; Sokoloff P; Schwartz JC; Launay C; Simon P; Costentin J; Schoenfelder A; Garrido F; Mann A
J Pharmacol Exp Ther; 1995 Dec; 275(3):1239-46. PubMed ID: 8531087
[TBL] [Abstract][Full Text] [Related]
4. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
Pugsley TA; Davis MD; Akunne HC; MacKenzie RG; Shih YH; Damsma G; Wikstrom H; Whetzel SZ; Georgic LM; Cooke LW
J Pharmacol Exp Ther; 1995 Dec; 275(3):1355-66. PubMed ID: 8531103
[TBL] [Abstract][Full Text] [Related]
5. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
[TBL] [Abstract][Full Text] [Related]
6. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.
Millan MJ; Peglion JL; Vian J; Rivet JM; Brocco M; Gobert A; Newman-Tancredi A; Dacquet C; Bervoets K; Girardon S
J Pharmacol Exp Ther; 1995 Nov; 275(2):885-98. PubMed ID: 7473180
[TBL] [Abstract][Full Text] [Related]
7. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
[TBL] [Abstract][Full Text] [Related]
8. [3H]-quinelorane binds to D2 and D3 dopamine receptors in the rat brain.
Gackenheimer SL; Schaus JM; Gehlert DR
J Pharmacol Exp Ther; 1995 Sep; 274(3):1558-65. PubMed ID: 7562534
[TBL] [Abstract][Full Text] [Related]
9. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
10. SB-277011 GlaxoSmithKline.
Remington G; Kapur S
Curr Opin Investig Drugs; 2001 Jul; 2(7):946-9. PubMed ID: 11757796
[TBL] [Abstract][Full Text] [Related]
11. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.
Sarau HM; Griswold DE; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Webb EF; Martin LD; Legos JJ; Whitmore RG; Barone FC; Medhurst AD; Luttmann MA; Giardina GA; Hay DW
J Pharmacol Exp Ther; 2000 Oct; 295(1):373-81. PubMed ID: 10992004
[TBL] [Abstract][Full Text] [Related]
12. Acute and chronic administration of the selective D(3) receptor antagonist SB-277011-A alters activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study.
Ashby CR; Minabe Y; Stemp G; Hagan JJ; Middlemiss DN
J Pharmacol Exp Ther; 2000 Sep; 294(3):1166-74. PubMed ID: 10945873
[TBL] [Abstract][Full Text] [Related]
13. In vivo occupancy of dopamine D3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder.
Barth V; Need AB; Tzavara ET; Giros B; Overshiner C; Gleason SD; Wade M; Johansson AM; Perry K; Nomikos GG; Witkin JM
J Pharmacol Exp Ther; 2013 Feb; 344(2):501-10. PubMed ID: 23197772
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.
Merchant KM; Gill GS; Harris DW; Huff RM; Eaton MJ; Lookingland K; Lutzke BS; Mccall RB; Piercey MF; Schreur PJ; Sethy VH; Smith MW; Svensson KA; Tang AH; Vonvoigtlander PF; Tenbrink RE
J Pharmacol Exp Ther; 1996 Dec; 279(3):1392-403. PubMed ID: 8968364
[TBL] [Abstract][Full Text] [Related]
15. [3H] A-369508 ([2-[4-(2-cyanophenyl)-1-piperazinyl]-N-(3-methylphenyl) acetamide): an agonist radioligand selective for the dopamine D4 receptor.
Moreland RB; Terranova MA; Chang R; Uchic ME; Matulenko MA; Surber BW; Stewart AO; Brioni JD
Eur J Pharmacol; 2004 Aug; 497(2):147-54. PubMed ID: 15306199
[TBL] [Abstract][Full Text] [Related]
16. 1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1, 3-dihydroimidazol-2-one: a selective high-affinity antagonist for the human dopamine D(4) receptor with excellent selectivity over ion channels.
Carling RW; Moore KW; Moyes CR; Jones EA; Bonner K; Emms F; Marwood R; Patel S; Patel S; Fletcher AE; Beer M; Sohal B; Pike A; Leeson PD
J Med Chem; 1999 Jul; 42(14):2706-15. PubMed ID: 10411491
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
[TBL] [Abstract][Full Text] [Related]
18. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
[TBL] [Abstract][Full Text] [Related]
19. The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats.
Gyertyán I; Sághy K
Eur J Pharmacol; 2007 Oct; 572(2-3):171-4. PubMed ID: 17628535
[TBL] [Abstract][Full Text] [Related]
20. I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor.
Tallman JF; Primus RJ; Brodbeck R; Cornfield L; Meade R; Woodruff K; Ross P; Thurkauf A; Gallager DW
J Pharmacol Exp Ther; 1997 Aug; 282(2):1011-9. PubMed ID: 9262370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
